Table 3.
Immunological responses and clinical responses
| Patient No. | Peptide | Peptide-specific IgGa | Peptide-specific IFN-γ productionb | Cytotoxicity | Clinical response | Number of vaccination | TTP (day) | OS (day) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post-vaccination | Pre | Post-vaccination | |||||||||
| 5th | 10th | 5th | 10th | |||||||||
| 1 | SART3 109 | 550 | 776 | 446 | 79 | 26 | 169 | SD | 28 | 206 | 376 | |
| Lck 488 | 151 | 243 | 102 | 186 | 118 | 0 | ||||||
| PAP 213 | 164 | 243 | 200 | 25 | 65 | 40 | ||||||
| 2 | Lck 486 | 135 | 257 | 265 | NT | 27 | 0 | PD | 19 | 69 | 659 | |
| Her2/neu 553 | 45 | 117 | 6,676 | NT | 33 | 0 | ||||||
| CEA 425 | 126 | 254 | 242 | NT | 51 | 0 | ||||||
| PTHrp 102 | 60 | 140 | 136 | NT | 114 | 0 | ||||||
| 3 | SART3 109 | 404 | 463 | NT | 0 | 0 | NT | PD | 6 | 35 | 38 | |
| Lck 486 | 44 | 49 | NT | 0 | 0 | NT | ||||||
| MRP3 1293 | 26 | 27 | NT | 0 | 0 | NT | ||||||
| SART1 690 | 9 | 7 | NT | 0 | 0 | NT | ||||||
| 4 | SART3 109 | 228 | 1,425 | 13,078 | 30 | 0 | 354 | + | SD (MR) | 31 | 309 | 1125+ |
| Her2/neu 553 | 142 | 147 | 25,684 | 0 | 38 | 0 | ||||||
| CEA 425 | 486 | 822 | 1,205 | 0 | 0 | 1,132 | ||||||
| MRP3 1293 | 386 | 465 | 558 | 0 | 0 | 40 | ||||||
| 5 | UBE2 V 43 | 1927 | 1708 | 4,315 | 1,687 | 2,542 | 2,170 | SD (MR) | 21 | 200 | 1023 | |
| EIF4EBP 51 | 640 | 487 | 451 | 1,206 | 0 | 0 | ||||||
| WHSC2 103 | 490 | 415 | 392 | 528 | 181 | 127 | ||||||
| CypB 129 | 366 | 235 | 223 | 1,293 | 0 | 0 | ||||||
| 6 | SART3 109 | 320 | 202 | NT | 35 | 14 | NT | PD | 8 | 50 | 595 | |
| MRP3 1293 | 36 | 22 | NT | 0 | 799 | NT | ||||||
| EGFR 800 | 23 | 14 | NT | 0 | 25 | NT | ||||||
| PSCA 76 | NT | NT | NT | 0 | 12 | NT | ||||||
| 7 | SART2 93 | 250 | 189 | NT | 0 | 0 | NT | PD | 6 | 37 | 207 | |
| SART3 109 | 720 | 1,907 | NT | 31 | 295 | NT | ||||||
| MRP3 1293 | 941 | 4,779 | NT | 164 | 1,340 | NT | ||||||
| Her2/neu 553 | 748 | 530 | NT | 629 | 129 | NT | ||||||
| 8 | SART3 109 | 572 | 4,779 | 21,235 | 97 | 906 | 174 | + | SD (MR) | 36 | 357 | 1002+ |
| MRP3 1293 | 146 | 124 | 5,592 | 56 | 27 | 168 | ||||||
| Lck 486 | 76 | 64 | 347 | 53 | 44 | 42 | ||||||
| SART2 93 | 43 | 26 | 35 | 0 | 0 | 593 | ||||||
| 9 | SART3 109 | 231 | 222 | 234 | 0 | 3,236 | 2,868 | PD | 11 | 75 | 315 | |
| MRP3 1293 | 40 | 36 | 32 | 14 | 0 | 0 | ||||||
| Her2/neu 553 | 36 | 30 | 31 | 128 | 0 | 6,121 | ||||||
| Lck 488 | 46 | 41 | 42 | 0 | 0 | 2,101 | ||||||
| 11 | SART3 302 | <10 | 768 | 376 | 354 | 0 | 0 | + | PD | 11 | 35 | 450 |
| SART3 309 | <10 | <10 | 25 | 0 | 13,459 | 0 | ||||||
| Lck 246 | <10 | <10 | 154 | 0 | 3,966 | 5,130 | ||||||
| WHSC2 141 | <10 | <10 | <10 | 0 | 349 | 3,843 | ||||||
| 12 | SART3 109 | 448 | 442 | 684 | 73 | 198 | 1,425 | + | SD | 17 | 187 | 725+ |
| Lck 486 | 161 | 179 | 161 | 44 | 76 | 328 | ||||||
| MRP3 1293 | 392 | 610 | 1,177 | 256 | 48 | 0 | ||||||
| PTHrp 102 | 52 | 53 | 49 | 0 | 64 | 827 | ||||||
| 13 | SART2 161 | 2,529 | 1,929 | 2,500 | 27 | 41 | 331 | PD | 15 | 44 | 368 | |
| Lck 486 | 1,486 | 1,397 | 1,409 | 31 | 0 | 0 | ||||||
| MRP3 1293 | 4,463 | 4,011 | 4,240 | 0 | 0 | 0 | ||||||
| PAP 213 | 4,165 | 4,226 | 9,379 | 0 | 0 | 943 | ||||||
| 14 | SART3 109 | 127 | 115 | 127 | 393 | 2,352 | 432 | SD | 17 | 168 | 657+ | |
| Lck 486 | 47 | 38 | 39 | 92 | 0 | 201 | ||||||
| PAP 213 | 155 | 121 | 2,966 | 24 | 0 | 5,936 | ||||||
| PSA 248 | 45 | 36 | 79 | 0 | 0 | 344 | ||||||
NT not tested, TTP time to progression, OS overall survival time, SD stable disease, PD progressive disease, MR minor response
aValue indicates fluorescence intensity units (FIU) of a peptide-specific IgG antibodies level in sera. An increase in FIU was considered to be positive when the absolute value was more than two times higher than that in a prevaccination sample. Positive values are shown in bold
bValue indicates interferon (IFN)-γ production (pg/mL) of peripheral blood mononuclear calls (PBMC) reactive to the vaccinated peptide. An increase in IFN-γ production was considered to be positive when the value was more than two times and 100 pg/mL higher than that in a prevaccination sample